Interleukin-12A (IL12A), also known as p35. is a subunit of the heterodimeric cytokine IL-12. which plays a critical role in bridging innate and adaptive immunity. IL-12. composed of IL12A (p35) and IL12B (p40), is primarily produced by antigen-presenting cells and induces Th1 cell differentiation, promotes IFN-γ production, and enhances cytotoxic T/NK cell activity. Dysregulation of IL-12 signaling is linked to autoimmune diseases, infections, and cancer.
IL12A antibodies are immunological tools designed to specifically detect, neutralize, or modulate IL12A activity. Monoclonal antibodies targeting IL12A are used in research to study IL-12/IL-23 signaling pathways, while therapeutic antibodies (e.g., ustekinumab) often target shared p40 subunits of IL-12 and IL-23 to treat conditions like psoriasis or inflammatory bowel disease. However, IL12A-specific antibodies allow precise investigation of IL-12-driven immune responses without interfering with IL-23.
In diagnostics, IL12A antibodies aid in quantifying IL-12 levels in inflammatory or infectious disease models. Challenges include ensuring specificity due to structural similarities between cytokine subunits. Recent advancements in recombinant antibody engineering have improved their application in immunotherapy and mechanistic studies, highlighting IL12A's potential as a biomarker or therapeutic target in immune-mediated disorders.